Plant-Based Vaccine Antigen Production
Abstract
The transient and stable expression of potentially therapeutic proteins in plants is a promising tool for the efficient production of vaccines and antibodies at low cost connected with a practically unlimited scale-up. To achieve these goals, two major challenges, inadequate production levels and non-scalable purification technologies, have to be overcome. Here we present and discuss protocols enabling to perform influenza vaccine production by transient expression in tobacco plants, to perform analytical experiments as Western blot, ELISA, and hemagglutination assays and to purify the antigens by classical affinity chromatography and scalable membrane-based Inverse Transition Cycling.
Key words
Influenza vaccine Membrane-based inverse transition cycling ELPylation Plant-derived hemagglutinin Hemagglutinin trimerNotes
Acknowledgement
This work is supported by a grant from the Bundesministerium für Bildung und Forschung (Bioeconomy International).
References
- 1.Yusibov V, Rabindran S (2008) Recent progress in the development of plant derived vaccines. Expert Rev Vaccines 7:1173–1183CrossRefPubMedGoogle Scholar
- 2.Phan HT, Floss DM, Conrad U (2013) Veterinary vaccines from transgenic plants: highlights of two decades of research and a promising example. Curr Pharm Des 19:5601–5611CrossRefPubMedGoogle Scholar
- 3.Evangelista RL, Kusnadi AR, Howard JA et al (1998) Process and economic evaluation of the extraction and purification of recombinant beta-glucuronidase from transgenic corn. Biotechnol Prog 14:607–614CrossRefPubMedGoogle Scholar
- 4.Floss DM, Schallau K, Rose-John S et al (2010) Elastin-like polypeptides revolutionize recombinant protein expression and their biomedical application. Trends Biotechnol 28:37–45CrossRefPubMedGoogle Scholar
- 5.Phan HT, Hause B, Hause G et al (2014) Influence of elastin-like polypeptide and hydrophobin on recombinant hemagglutinin accumulations in transgenic tobacco plants. PLoS One 9:e99347PubMedCentralCrossRefPubMedGoogle Scholar
- 6.World Health Organization. Influenza at the human-animal interface (HAI). http://www.who.int/influenza/human_animal_interface/en/. Accessed 25 June 2013
- 7.Cornelissen LAHM, de Vries RP, de Boer-Luijtze EA et al (2010) A single immunization with soluble recombinant trimeric hemagglutinin protects chickens against highly pathogenic avian influenza virus H5N1. PLoS One 5:e10645PubMedCentralCrossRefPubMedGoogle Scholar
- 8.Phan HT, Pohl J, Floss DM et al (2013) ELPylated haemagglutinins produced in tobacco plants induce potentially neutralizing antibodies against H5N1 viruses in mice. Plant Biotechnol J 11:582–593CrossRefPubMedGoogle Scholar
- 9.Phan HT, Conrad U (2011) Membrane-based inverse transition cycling: an improved means for purifying plant-derived recombinant protein-elastin-like polypeptide fusions. Int J Mol Sci 12:2808–2821PubMedCentralCrossRefPubMedGoogle Scholar
- 10.Laemmli UK (1970) Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 227:680–685CrossRefPubMedGoogle Scholar
- 11.Meyer DE, Chilkoti A (1999) Purification of recombinant proteins by fusion with thermally-responsive polypeptides. Nat Biotechnol 17:1112–1115CrossRefPubMedGoogle Scholar
- 12.Scheller J, Henggeler D, Viviani A, Conrad U (2004) Purification of spider silk-elastin from transgenic plants and application for human chondrocyte proliferation. Transgenic Res 13:51–57CrossRefPubMedGoogle Scholar
- 13.Ge X, Trabbic-Carlson K, Chilkoti A, Filipe CDM (2006) Purification of an elastin-like fusion protein by microfiltration. Biotechnol Bioeng 95:424–432CrossRefPubMedGoogle Scholar